Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics. The main results are: (1) All of the 4 new drugs are more effective than placebo, but the magnitude of the effect is only moderate [mean effect size, r, of all antipsychotics vs. placebo = 0.25, with a 95% confidence interval (CI) = 0.22-0.28, n = 2477]. (2) According to the studies published to date, sertindole and quetiapine are as effective as haloperidol, and risperidone and olanzapine are slightly more effective than haloperidol in the treatment of global schizophrenic symptomatology. (3) With respect to negative symptoms, all new antipsychotics are more effective than placebo. However, contrary to widespread opinion, so is the 'conventional' antipsychotic haloperidol. Risperidone and olanzapine are slightly superior, sertindole is as effective and--according to the only study fully published to date--quetiapine is even slightly less effective than haloperidol in this regard. (4) All new antipsychotics are associated with less frequent use of antiparkinson medication than haloperidol, with risperidone appearing to have a slightly less favourable EPS-profile than the other new antipsychotics. The methodological limitations of this review, the generalizability of the results and expectations from future research are discussed.

• Publication year

  1999

• Venue

  Schizophrenia Research

• Publication date

  1999-01-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0920-9964(98)00105-4PMID 9988841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clozapine versus typical neuroleptic medication for schizophrenia.

  2000cited by this paper
• Expert Consensus Guideline Series Treatment of Schizophrenia 1999

  1999cited by this paper
• Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety.

  1998cited by this paper
• What is an atypical antipsychotic?

  1997cited by this paper
• Efficacy of olanzapine: an overview of pivotal clinical trials.

  1997cited by this paper
• Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

  1997cited by this paper
• Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

  1997cited by this paper
• Discrepancies between meta-analyses and subsequent large randomized, controlled trials.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

  1997cited by this paper
• Atypical neuroleptics in the treatment of early onset schizophrenia.

  1997cited by this paper
• Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

  1997cited by this paper
• Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety

  1997cited by this paper
• A double‐blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment‐refractory schizophrenia

  1997cited by this paper
• New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses

  1997cited by this paper
• A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

  1997cited by this paper
• Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials.

  1997cited by this paper
• Safety of olanzapine.

  1997cited by this paper
• Clinical experience in developing treatment regimens with the novel antipsychotic risperidone

  1997cited by this paper
• Risperidone: an analysis of the first three years in general use

  1997cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Extrapyramidal symptoms in patients treated with risperidone.

  1997cited by this paper
• Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia

  1997cited by this paper
• Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

  1997cited by this paper
• Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association.

  1997cited by this paper
• Olanzapine: A New Antipsychotic Agent with Efficacy in the Management of Schizophrenia

  1997cited by this paper
• Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic.

  1997cited by this paper
• A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.

  1997cited by this paper
• Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

  1997cited by this paper
• Risperidone: how good is the evidence for efficacy?

  1997cited by this paper
• Direct effect of sertindole on the primary negative symptoms of schizophrenia: A PATH analysis

  1997cited by this paper
• Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

  1997cited by this paper
• A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

  1997cited by this paper
• ‘Seroquel’™ (ICI 204,636) EPS and Prolactin: Comparison with Haloperidol

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: ‘Seroquel’ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic

  1996cited by this paper
• Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

  1996cited by this paper
• Akathisia and Restless Legs

  1996cited by this paper
• ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.

  1996cited by this paper
• Sertindole

  1996cited by this paper
• ICI 204, 636: A New Atypical Antipsychotic Drug

  1996cited by this paper
• Olanzapine versus Placebo and Haloperidol

  1996cited by this paper
• A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

  1996cited by this paper
• The new generation of antipsychotic drugs

  1996cited by this paper
• Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.

  1996cited by this paper
• Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

  1996cited by this paper
• ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

  1995cited by this paper
• A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients

  1995cited by this paper
• Clinical Efficacy of Serotonin‐Dopamine Antagonists Relative to Classic Neuroleptics

  1995cited by this paper
• New antipsychotics: the present status

  1995cited by this paper
• Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial

  1995cited by this paper
• Risperidone in the treatment of negative symptoms of schizophrenia: a meta‐analysis

  1995cited by this paper
• Risperidone: efficacy and safety.

  1995cited by this paper
• Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

  1995cited by this paper
• Efficacy and safety of sertindole in a trial of schizophrenic patients

  1995cited by this paper
• Risperidone in the treatment of schizophrenia.

  1994cited by this paper
• Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial.

  1994cited by this paper
• Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

  1994cited by this paper
• Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.

  1993cited by this paper
• Principles and Practice of Psychopharmacotherapy

  1993cited by this paper
• A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

  1993cited by this paper
• Clinical review of risperidone.

  1993cited by this paper
• Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

  1993cited by this paper
• Double-blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses

  1993cited by this paper
• Risperidone: clinical safety and efficacy in schizophrenia.

  1992cited by this paper
• The efficacy of psychotropic drugs: implications for power analysis.

  1992cited by this paper
• Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study

  1992cited by this paper
• Dosage of haloperidol for schizophrenia.

  1991cited by this paper
• Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

  1991cited by this paper
• A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.

  1990cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Treatment of schizophrenia.

  1987cited by this paper
• The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia

  1986cited by this paper
• Negative and deficit symptoms in schizophrenia do respond to neuroleptics.

  1985cited by this paper
• Treatment of negative symptoms.

  1985cited by this paper
• Meta-analytic procedures for social research

  1984cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper
• Further meta-analytic procedures for assessing cognitive gender differences.

  1982cited by this paper
• Important issues in the drug treatment of schizophrenia.

  1980cited by this paper
• Molecular pathology of schizophrenia: more than one disease process?

  1980cited by this paper
• Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.

  1978cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper
• STATISTICAL METHODS

  1967cited by this paper
• PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP.

  1964cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• Action of Radiant-heat Cradles

  1943cited by this paper

• Predicting antipsychotic use in children.

  2025cites this paper
• IUPHAR REVIEW: Moving beyond dopamine-based therapeutic strategies for schizophrenia.

  2025cites this paper
• Effects of Clozapine, Haloperidol, and the NMDA Antagonist Ketamine on Novel Object Recognition in Gnathonemus petersii: A New Possible Model for Schizophrenia Research

  2025cites this paper
• Engineered Dual-Component Lipid-Polymer Nanoparticles for Modified Olanzapine Release, Shelf-Life Assessment, and Elevated Bioavailability in Schizophrenia Therapy

  2025cites this paper
• Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy.

  2025cites this paper
• Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.

  2024cites this paper
• The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.

  2024cites this paper
• Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.

  2024cites this paper
• Acid-blocked electron transfer: New photoluminescence approach for sensitive assay of quetiapine in dosage form: Application to content uniformity testing

  2024cites this paper
• THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.

  2024cites this paper
• Efficacy of Low-dose Olanzapine in Combination with Sertraline on Negative Symptoms and Psychosocial Functioning in Schizophrenia: A Randomized Controlled Trial

  2023cites this paper
• Factors influencing concentrations of risperidone and 9‐hydroxyrisperidone in psychiatric outpatients taking immediate‐release formulations of risperidone

  2023cites this paper
• Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets

  2023cites this paper
• Schizophrenie im Alter

  2023cites this paper
• Five‐year trend of antipsychotic prescription practices in a district Hospital in Ghana: A retrospective study

  2023cites this paper
• Prescribing of Antipsychotic Medication in a Medicaid Population: Prescribing of Antipsychotic Medication in a Medicaid Population: Use of Polytherapy and Off-Label Dosages Use of Polytherapy and Off-Label Dosages

  2023cites this paper
• Validation of the French Clinical Assessment Interview for Negative Symptoms in a Sample of Stable French Individuals With Schizophrenia

  2022cites this paper
• Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses

  2022cites this paper
• Olanzapine in the Treatment of Schizophrenia and How Its Response is Modulated by Variations in Certain Genes

  2022cites this paper
• Prevalence and Associated Risk Factors of Oral Mucosal Lesions and Orofacial Dyskinesia in Patients with Psychotic Disorders

  2022cites this paper
• Psychiatry and Society

  2021cites this paper
• From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era

  2021cites this paper
• Anti-psychiatry

  2021cites this paper
• Therapeutic use of melatonin in schizophrenia: A systematic review

  2021cites this paper
• Robust and Fast UV–HPLC Method for Biotransformation Analysis of Azecines

  2021cites this paper
• The Basal Ganglia

  2021cites this paper
• Cost-effectiveness analysis of interventions to achieve universal health coverage for schizophrenia in Mexico

  2020cites this paper
• Detecting Unipolar and Bipolar Depressive Disorders from Elicited Speech Responses Using Latent Affective Structure Model

  2020cites this paper
• Transdermal delivery of second-generation antipsychotics for management of schizophrenia; disease overview, conventional and nanobased drug delivery systems

  2020cites this paper
• Examining the dispensing patterns of antipsychotics in Australia from 2006 to 2018 - A pharmacoepidemiology study.

  2020cites this paper
• Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)

  2020cites this paper
• Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia.

  2020cites this paper
• Cell-Coupled Long Short-Term Memory With $L$ -Skip Fusion Mechanism for Mood Disorder Detection Through Elicited Audiovisual Features

  2020cites this paper
• The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia

  2020cites this paper
• Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia

  2020cites this paper
• The influence of genetic and epigenetic factors as covariates of the tolerability and therapeutic response to olanzapine in the treatment of psychotic diseases

  2020cites this paper
• Negative Symptoms and Their Assessment in Schizophrenia and Related Disorders

  2020cites this paper
• Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults‐a propensity score matched cohort study

  2020cites this paper
• One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study

  2020cites this paper
• Serotonin and schizophrenia

  2020cites this paper
• Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.

  2020cites this paper
• Treating schizophrenia: the quality of evidence behind treatment recommendations and how it can improve

  2019cites this paper
• Analysis of phenformin hydrochloride and atypical antipsychotics in plasma using surface-enhanced Raman scattering

  2019cites this paper
• Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor.

  2019cites this paper
• A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

  2019cites this paper
• NDT_A_209284 2559..2569

  2019cites this paper
• Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy

  2019cites this paper
• Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011.

  2019cites this paper
• A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia

  2019cites this paper
• Pharmacological Interventions in Older Adults

  2019cites this paper
• Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings

  2019cites this paper
• Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA

  2019cites this paper
• The effect of baseline antipsychotic status on the 12‐month outcome in initially stabilized patients with schizophrenia

  2019cites this paper
• Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets

  2019cites this paper
• Haloperidol versus olanzapine for people with schizophrenia

  2019cites this paper
• Investigating the Roles of Parvalbumin and Cholecystokinin Interneurons of the Ventral Hippocampus and Medial Prefrontal Cortex in Schizophrenia-Related Behaviours

  2018cites this paper
• How Are Individual Differences in Schizotypy Related to Type 1 (Automatic/Heuristic) and Type 2 (Reflective/Effortful) Thinking Processes?

  2018cites this paper
• Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.

  2018cites this paper
• Acute anti-psychotic modulation of the structure and function of the brain

  2018cites this paper
• Attention Deficit Hyperactivity Disorder in people with Intellectual Disability

  2018cites this paper
• Genderwise clinical response of antipsychotics among schizophrenic patients: a prospective observational study from Lahore, Pakistan

  2018cites this paper
• Long-term follow-up of clozapine prescribing

  2018cites this paper
• Successful treatment of psychosis in dentatorubral‐pallidoluysian atrophy with quetiapine: A case report

  2018cites this paper
• Metacognition in psychotic disorders

  2018cites this paper
• Functional recovery in patients with schizophrenia: recommendations from a panel of experts

  2018cites this paper
• Accessing Gene Expression in Treatment-Resistant Schizophrenia

  2018cites this paper
• SEX DIFFERENCES IN THE BEHAVIOURAL RESPONSES TO OLANZAPINE IN RATS A thesis submitted in partial fulfilment of the Requirements for the Degree of Master of Science in Psychology By

  2018cites this paper
• Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.

  2018cites this paper
• Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low‐potency antipsychotics

  2017cites this paper
• Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.

  2017cites this paper
• Spiroperidol, but not eticlopride or aripiprazole, produces gradual increases in descent latencies in the bar test in rats

  2017cites this paper
• Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study

  2017cites this paper
• Case of Secondary Tics Associated With Olanzapine in an Adult

  2017cites this paper
• The Totara House Healthy Eating Study: A qualitative investigation into the feasibility of adapting the Senior Chef programme for patients in a mental health setting.

  2017cites this paper
• Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis.

  2017cites this paper
• Stability and development of psychotic symptoms and the use of antipsychotic medication – long-term follow-up

  2017cites this paper
• Olanzapine induced delirium-a "probable" adverse drug reaction.

  2017cites this paper
• Risperidone ameliorates cognitive deficits, promotes hippocampal proliferation, and enhances Notch signaling in a murine model of schizophrenia

  2017cites this paper
• Bionanocomposite systems based on montmorillonite and biopolymers for the controlled release of olanzapine.

  2017cites this paper
• Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?

  2017cites this paper
• Pre-clinical and Clinical Evaluation of selected Anti psychotics Induced Toxicity; Biochemical and Histopathological Approach

  2017cites this paper
• Comparative Safety Profile of Single Versus Combination Antipsychotic Therapy by Using Glassgow Antipsychotic Side Effect Scale (Gass)

  2017cites this paper
• 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice

  2017cites this paper
• Fenotipo y genotipo de los síntomas negativos en la esquizofrenia: conceptualización, evaluación y su relación con el polimorfismo val66met del bdnf

  2017cites this paper
• Cytochrome P450‐mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy

  2017cites this paper
• Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice

  2017cites this paper
• Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics

  2017cites this paper
• Study of adverse drug reactions of atypical antipsychotic drugs in the department of psychiatry in a tertiary care hospital of Assam

  2017cites this paper
• Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study

  2016cites this paper
• Overcoming Disembodiment: The Effect of Movement Therapy on Negative Symptoms in Schizophrenia—A Multicenter Randomized Controlled Trial

  2016cites this paper
• An extended cost-effectiveness analysis of schizophrenia treatment in India under universal public finance

  2016cites this paper
• Factors affecting adherence in patients with schizophrenia

  2016cites this paper
• Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series

  2016cites this paper
• Risperidone (depot) for schizophrenia.

  2016cites this paper
• Coupled HMM-based multimodal fusion for mood disorder detection through elicited audio–visual signals

  2016cites this paper
• Possible natural therapeutics against schizophrenia and its acute and treatment resistant forms: a review

  2016cites this paper
• Antipsychotic medications for cocaine dependence.

  2016cites this paper
• Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.

  2016cites this paper
• Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions

  2016cites this paper
• Monitoring of prolactin levels in children and adolescents prescribed antipsychotic medication: a complete audit cycle

  2016cites this paper